Ranibizumab biosimilar is under clinical development by Jecho Biopharmaceuticals and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase III drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ranibizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ranibizumab biosimilar overview
Ranibizumab biosimilar is under development for the treatment of age-related macular degeneration (AMD), wet age-related macular degeneration (wAMD) and other ophthalmic diseases. It acts by targeting vascular endothelial growth factor (VEGF). The drug candidate is a biosimilar. It is administered through intravitreal injection.
Jecho Biopharmaceuticals overview
Jecho Biopharmaceuticals is a biomedical company that manufactures and supplies monoclonal antibodies, recombinant proteins, immunotoxins, vaccines and other biopharmaceuticals. It is investigating JL14001, a novel recombinant protein to treat anemia caused by chemotherapy and chronic kidney diseases; JL14002 biosimilar against age related macular degeneration and other ophthalmic diseases; JL15003 for glioma; JL17001, JL18004 and CDMO 001 for the treatment of tumor. The company is evaluating JL18008 against lymphocytopenia and tumor immunotherapy; and CDMO 002 immunotoxin to treat hairy cell leukemia. Jecho Biopharmaceuticals is also developing bispecific and neutralizing antibodies to prevent COVID-19. The company utilizes its proprietary JechoBAPTS, JechMabs, JechoOptima, and JechoPilot platforms to develop antibodies. Jecho Biopharmaceuticals is headquartered in Tianjin, China.
For a complete picture of Ranibizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.